Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2016 Dec 1;73(4):396–402. doi: 10.1097/QAI.0000000000001074

Table 1. Baseline characteristics.

Characteristic Cases
n=73 (31%)
Controls,
n=157 (69%)
Male gender, n (%) 30 (41.10) 40 (25.48)

Age at ART initiation, median (IQR) 36 (32 - 43) 33 (28 - 38)

Smoking Status

 Never 53 (72.60) 119 (75.80)
 Past or current 18 (26.14) 36 (22.93)

BMI (Kg/m2) categories, n (%)

 < 25 50 (68.49) 128 (81.53)
 25 - 29.9 15 (20.55) 17 (10.83)
 ≥ 30 4 (5.48) 2 (1.27)
 Missing 4 (5.48) 10 (6.37)

CD4+ T cell counts (cells/mm3) at ART initiation, n (%)

 < 100 29 (39.73) 48 (30.57)
 100 – 249 35 (47.95) 82 (52.23)
 ≥ 250 9 (12.33) 27 (17.20)
 Missing 1 (1.37) 4 (2.55)

HIV viral load (Log10/mm3), median (IQR) 5.09 (4.72 - 5.63) 5.07 (4.60 - 5.50)

Duration of observation until censor (years), median (IQR) 7.29 (6.37 - 7.87) 5.76 (1.59 - 7.14)

Clinic visits with blood pressure measurement during observation, median (IQR) 35 (29 - 38) 27 (13 - 36)

BMI: Body mass index; ART: Antiretroviral therapy; CD4: cluster differentiation cells; IQR: interquartile range